Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)Ĭalendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.Ĭryptocurrencies: Cryptocurrency quotes are updated in real-time. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Provided by PR Newswire 1:30 PM UTC Co-Diagnostics, Inc. This suggests a possible upside of 62.6 from the stock's current price. to Present at 15th Next Generation Dx Summit in Washington, D.C. On average, they predict the company's share price to reach 2.00 in the next year. Their CODX share price forecasts range from 2.00 to 2.00. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv. 2 Wall Street research analysts have issued 12 month price objectives for Co-Diagnostics' stock. Data may be intentionally delayed pursuant to supplier requirements. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Source: FactSetĭata are provided 'as is' for informational purposes only and are not intended for trading purposes. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Sources: FactSet, Tullett PrebonĬommodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Sources: FactSet, Tullett PrebonĬurrencies: Currency quotes are updated in real-time. Sources: FactSet, Dow Jonesīonds: Bond quotes are updated in real-time. Sources: FactSet, Dow JonesĮTF Movers: Includes ETFs & ETNs with volume of at least 50,000. Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Overview page represent trading in all U.S. Indexes: Index quotes may be real-time or delayed as per exchange requirements refer to time stamps for information on any delays. Copyright © FactSet Research Systems Inc. Fundamental company data and analyst estimates provided by FactSet. International stock quotes are delayed as per exchange requirements. stock quotes reflect trades reported through Nasdaq only comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Awarded Funding for Co-Dx PCR Home Platform from NIH RADx(R) Tech Program Announces Recent Grant AwardsĬo-Diagnostics, Inc. to Host Booth and Discuss Recent Grant Awards at AACC 2023 in Anaheim, CAĬo-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and WebcastĬo-Diagnostics, Inc. Reports Second Quarter 2023 Financial ResultsĬo-Diagnostics, Inc. (NASDAQ:NASDAQ:CODX) Q2 2020 Earnings Conference Call Aug4:30 PM ETCompany ParticipantsAndrew Benson - IRDwight H Egan - CEOReed Benson - CFOConference Call. to Host Booth at Medlab Asia Conference in Bangkok, ThailandĬo-Diagnostics, Inc. to Present at 15th Next Generation Dx Summit in Washington, D.C.Ĭo-Diagnostics, Inc. Grabar Law Office Investigates Claims on Behalf of Shareholders of Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer
Wainwright 25th Annual Global Investment Conference on September 11-13, 2023Ĭo-Diagnostics, Inc. CODX Significant News OnlyĬo-Diagnostics, Inc. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.News Co-Diagnostics Inc.
#Co diagnostics inc co dx portable#
The Company is also developing a portable polymerase chain reaction (PCR) device and test cups that are designed to bring PCR to patients in point-of-care and even at-home settings. It also sells diagnostic equipment from other manufacturers as self-contained lab systems. It also uses its technology to design specific tests for its Co-Dx PCR Home platform and to locate genetic markers for use in applications other than infectious disease. The Company is engaged in developing, manufacturing and selling reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, including molecular tools for the detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.
0 kommentar(er)
